Clinical trial starts for prospective ALS treatment co-developed at Scripps Research Experimental drug 3K3A-APC has shown broad brain-protecting effects in animal studies.
December 17, 2021
LA JOLLA, CA An experimental treatment called 3K3A-APC, which was co-developed at Scripps Research and has shown promise against amyotrophic lateral sclerosis (ALS) in preclinical studies, is now being tested in patients with the disease.
The clinical trial, at Macquarie University in Sydney, Australia, will enroll a total of 16 ALS patients, and aims to provide evidence of the experimental treatment's safety and effectiveness against ALS a progressive neurodegenerative disease that is usually fatal and has no cure.
Often called Lou Gehrig's disease (after the famous baseball player who died of it in 1941), ALS is estimated to afflict up to 20,000 people in the United States at any one time. The disorder features the progressive deaths of muscle-controlling neurons, causing weakness and paralysis in muscle groups and ultimately leading to respiratory failure and death. Despite decades of intensive research, scientists still have not identified the precise causes of ALS in its most common, non-inherited form, and, largely for that reason, there is no Food and Drug Administration (FDA)-approved treatment that markedly improves this condition.
I'm very hopeful that 3K3A-APC will benefit these patients in preclinical tests it has displayed remarkable anti-inflammatory, anti-programmed-cell-death, and other cell-stabilizing activities, says John Griffin, PhD, a professor in the Department of Molecular Medicine at Scripps Research whose lab invented 3K3A-APC.
Griffin initially developed and studied 3K3A-APC with University of Southern California (USC) researcher Berislav Zlokovic, MD, PhD. Zlokovic co-founded Houston-based ZZ Biotech, which has taken 3K3A-APC through advanced preclinical and early clinical development and which provides it for this ALS trial.
The 3K3A-APC drug is a modified version of a natural human protein, activated protein C (APC), which works as a powerful anticoagulant and also has neuroprotective properties. To minimize its chances of causing brain bleeding when used as a treatment, Griffin's lab altered APC in a way that removes 90 percent of its anticoagulant effect without removing its other neuroprotective properties.
Preclinical studies by the researchers and their colleagues have found that 3K3A-APC slows disease progression and extends survival in a commonly used mouse model of ALS. The protein appears to have this effect by delaying the activation of inflammation-promoting immune cells in the brain and spinal cord. The molecule also restores the integrity of the special blood-vessel-lining cells that protect the brain and spinal cord from immune cells and other potentially harmful factors in the blood.
The new clinical trial is being led by neurology Professor Dominic Rowe, MD, PhD, at the Macquarie University Centre for Motor Neuron Disease Research, one of the leading ALS research institutions in Australia. The trial is a Phase 2 open label trial (NCT05039268) that will assign 16 ALS patients to one of two doses of the treatment. The principal goal is to demonstrate the safety and tolerability of 3K3A-APC in ALS patients, although the results may also provide preliminary evidence that the treatment slows the ALS disease process.
Translational Medicine Griffin, John
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
07/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/05/2026
Recreating the 1974 Doctor Who Time Tunnel in After Effects
Graham Quince May 6, 2026
0 Comments
The Time Tunnel from Doctor Who titles is one of th...
06/05/2026
Gravity Media Chief RF Communications Engineer Glenn Willems uses Wisycom RF over Fiber and wireless solutions across major cycling events and international mar...
06/05/2026
A Sennheiser Spectera module is now available in Bitfocus Companion and Buttons, enabling direct integration of Spectera with the two software platforms. The mo...
06/05/2026
Ted Turner, the visionary media entrepreneur whose appetite for disruption helpe...
06/05/2026
Peacock is going all-in on the beautiful game - streaming all 104 FIFA World Cup...
06/05/2026
New pricing tiers for vocal/dialogue restoration tool
NoiseWorks Audio's AI-powered vocal and dialogue processing plug-in is now available in three diff...
06/05/2026
Popular mixing & routing software overhauled
Following a recent public beta test, RME have launched the final release version of the powerful mixing and rou...
06/05/2026
New SOS Video Feature
Focusrites ISA C8X is a milestone product that brings together the companys analogue heritage and their expertise in digital audio. Yo...
06/05/2026
Polands Miecznik-class frigates are part of the largest contract in Polish shipbuilding history. (Image Credit: PGZ Stocznia Wojenna)...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Riedel Communications today announced the expansion of its leadership structure as part of a strategic initiative to strengthen both its operational management ...
06/05/2026
For nearly three decades, Veteran Production Sound Mixer and Five-time Emmy Award Winner Dirk Sciarrotta has helped define the sonic identity of the long-runnin...
06/05/2026
ZEISS CinCraft LensCore: Cinema Lens Looks for Compositing
Brie Clayton May 6, 2026
0 Comments
ZEISS announces the launch of CinCraft LensCore, a nove...
06/05/2026
Wisycom Solves Extreme RF Challenges Across Miles of Live Action for Gravity Med...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Narrative Entertainment has partnered with Encompass to deliver high-quality subtitling of its Great! network content using the Altitude Intelligence AI assiste...
06/05/2026
SipRadius, widely recognized for making content processing and connectivity secure and seamless, is proud to launch a dramatic new approach to AI content creati...
06/05/2026
When the broadband and media industry gathers at ANGA COM in Cologne from May 19 to 21, Big Blue Marble will be at the forefront. The international broadcast an...
06/05/2026
Cinegy GmbH, a leading developer of software-defined television technology, is proud to exhibit at MPTS for the first time. Visitors to the stand will discover ...
06/05/2026
Val Jeanty Receives 2026 Doris Duke Artist Award Jeanty, a composer, percussionist, and turntablist, is the fourth Berklee recipient of the prestigious award ...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
When live cycling races and international marathons stretch for miles across cities and countryside, there is no margin for RF failure in live broadcast. As Chi...
06/05/2026
Oberkochen/Germany, May 5, 2026
ZEISS announces the launch of CinCraft LensCore, a novel solution for creating physically based cinematic lens looks for visual...
06/05/2026
06 May 2026
VEON's Kyivstar Authorized to Resell Starlink for Businesses & ...
06/05/2026
UKTV has secured the exclusive rights to the early back catalogue of iconic Australian drama series Neighbours, following a landmark content deal with Fremantle...
06/05/2026
Wednesday 6 May 2026
Sky commissions feature documentary to mark 10th anniversa...
06/05/2026
Wednesday 6 May 2026
Sky and Formula 1 agree long-term partnership across UK, Ireland and Italy
Sky in the UK & Ireland to remain the home of Formula 1 until ...
06/05/2026
Sky Zero Footprint Fund-backed TV campaign launches nationwide, supported by new...
06/05/2026
Wuppertal May 6, 2026
Riedel Expands Leadership Structure, Appoints Marc Engro...
06/05/2026
SAN JOSE, Calif. - May 6, 2026 - Harmonic (NASDAQ: HLIT) today announced its latest broadband innovations for ANGA COM 2026, highlighting its vision for a new e...
06/05/2026
Statement from Rupert Murdoch, Chairman Emeritus, Fox Corporation on Ted Turner&...
06/05/2026
Friday 8 May on RT One and RT Player
Meet the NSPCA team caring for and protecting animals in need in this six-part series
Fly on the wall, six-part series...
06/05/2026
The race to build the world's most powerful AI factories demands networking ...
06/05/2026
How changes to proteins can alter drug interactions for new precision therapies Scripps Research team maps how chemical modifications to proteins affect drug bi...
05/05/2026
Experts from the world of academia, tech, business, politics and media convened for a Thomson Talks at the Cambridge Disinformation Summit in April. It's th...
05/05/2026
Three phones were hardwired for power and transmission to the truck; camera feat...
05/05/2026
The creative studio behind campaigns for the NBA, Fanatics Sportsbook & Casino, ...
05/05/2026
Nielsen has announced results from a co-viewing pilot program covering February&...
Clinical trial starts for prospective ALS treatment co-developed at Scripps Research Experimental drug 3K3A-APC has shown broad brain-protecting effects in animal studies. 
